Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
16.21
+0.21 (1.31%)
At close: Oct 30, 2025, 4:00 PM EDT
16.21
0.00 (0.00%)
After-hours: Oct 30, 2025, 4:29 PM EDT
Cogent Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
205
Market Cap
2.27B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 7.87M | -14.63M | -65.02% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
COGT News
- 6 days ago - Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 10 days ago - Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib - GlobeNewsWire
- 4 weeks ago - Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Cogent Biosciences, Inc. (COGT) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 2 months ago - Cogent Biosciences Announces Participation in the Citi Biopharma Conference - GlobeNewsWire
- 3 months ago - Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 4 months ago - Cogent: Positive Data In NonAdvSM Bodes Well For 2nd Half AdvSM Treatment Results - Seeking Alpha